Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
+ 4 more
Nothing from your lists
Invech Holdings, Inc. · “As a result of the completion of those transfers, Perez Jimenez became the controlling shareholder of the Company.”¶1
Scotts Miracle-Gro Co · “The Company redeemed all $250 million aggregate principal amount of its outstanding 5.250% senior notes due 2026.”¶1
Indivior Pharmaceuticals, Inc. · “On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December 23, 2014, as was amended on March 29, 2019 (the "Copacker Supply Agreement").”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
Lifeward Ltd. set October 30, 2026 as the date for its 2026 Annual and Extraordinary General Meeting of Shareholders.¶1
Shareholder proposals for inclusion in the proxy materials must be received by the Interim Chief Executive Officer on or before September 23, 2026, and proposals and nominations must comply with applicable rules and regulations.¶1¶2
On August 10, 2026, Stephen Ken Adair entered into two Stock Purchase Agreements to sell his controlling equity interests to Angel Javier Perez Jimenez.¶2
The agreements covered 88,000,000 shares of common stock and 300,000 shares of Series A Preferred Stock for aggregate consideration of $291,390.00.¶3
On August 24, 2026, the transfer of the shares was completed and Perez Jimenez became the controlling shareholder of the Company.¶1
Effective August 10, 2026, Adair resigned from all positions, and Perez Jimenez was appointed President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and sole Director.¶4¶5
On September 11, 2026, the company redeemed all $250.0 million aggregate principal amount of its outstanding 5.250% Senior Notes due 2026.¶2
The company renewed its $750 million accounts receivable facility with JPMorgan Chase Bank, N.A., extending its maturity to August 31, 2027.¶3
The company executed share repurchases totaling $25 million during August, beginning the $500 million share repurchase program authorized by the Board of Directors.¶4
The company reaffirmed Fiscal 2026 guidance including adjusted net income per share from continuing operations of $4.30 to $4.45 and free cash flow of $275 million.¶5¶6¶7
Tenable completed its private offering of $800,000,000 aggregate principal amount of 0.25% Convertible Senior Notes due 2031, including the initial purchasers’ exercise of an option to buy an additional $75,000,000 principal amount.¶1
The Notes mature on September 15, 2031, bear interest at 0.25% per year, and initially convert at 22.3005 shares per $1,000 principal amount, equivalent to approximately $44.84 per share.¶2¶3
Net proceeds were approximately $778.8 million; the Company paid approximately $64.1 million for capped calls, repurchased approximately $170.5 million of common stock, repaid its term loans, and terminated the Credit Agreement effective September 15, 2026.¶4
The Notes and shares issuable upon conversion were not registered, and based on the initial conversion rate, the Notes are convertible into 17,840,400 shares and, in limited circumstances, a maximum of 24,976,560 shares.¶5¶6
On September 15, 2026, Pulse Biosciences entered into an equity distribution agreement with Mizuho to offer and sell Common Stock having an aggregate offering price of up to $85,000,000.¶1
The Company is not obligated to sell Shares, and will pay Mizuho compensation at a commission rate of up to 3.0% of the gross sales price of Shares sold.¶2
As of September 14, 2026, 1,379,925 shares had been issued and sold under the August 2026 Sales Agreement, for an aggregate offering price of approximately $68.8 million.¶3
On September 14, 2026, the Company terminated its TD Cowen Distribution Agreement, with shares having an aggregate offering price of up to $1.0 million remaining unsold.¶4
On September 15, 2026, AEye, Inc. entered into an At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners to offer and sell common stock up to $50,000,000.¶2¶3¶1
The Company intends to use net proceeds from the Placement Shares for working capital and general corporate purposes, including research and development, commercial activities, capital expenditures, and administrative expenses.¶4
The Company and A.G.P. terminated the Prior Sales Agreement effective upon execution of the new Sales Agreement, and the Company incurred no early termination penalties.¶5
Jaguar Health’s board approved a one-for-fifteen reverse stock split, filed the amendment on September 14, 2026, and scheduled effectiveness for 12:01 am Eastern Time on September 17, 2026.¶1
The Reverse Stock Split will reclassify every fifteen (15) shares of Common Stock into one (1) share, without changing par value per share, and will proportionately adjust options, warrants, and reserved equity-plan shares.¶1
No fractional shares will be issued, stockholders entitled to fractional shares will receive cash, and trading will continue on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis beginning September 17, 2026.¶2¶3
The Company sold 225,000 shares of Series B Convertible Preferred Stock to institutional investors for $225.0 million at the September 14, 2026 First Closing.¶1¶2
The Company used First Closing proceeds to redeem all outstanding Series A Convertible Preferred Stock at $1,028.50 per share, totaling approximately $154.3 million.¶3¶4
Subject to the Merger conditions, the Company agreed to sell 450,000 additional Series B Convertible Preferred Stock shares at a Second Closing.¶5¶2
The Series B Convertible Preferred Stock carries 12.00% cumulative dividends, conversion rights after the sixth anniversary, and limits conversion issuance above 19.99% without shareholder approval.¶6¶7¶8
On September 14, 2026, GT Biopharma entered into a Securities Purchase Agreement for up to 8,277.778 shares of Series M 10% Convertible Preferred Stock and warrants, with an aggregate stated value of $8,277,778 for an aggregate purchase price of $7,450,000.¶1
Each Purchaser may elect to purchase Preferred Stock with an aggregate stated value of up to $33,333,333 for an aggregate purchase price of $30,000,000, subject to adjustments.¶2
The Preferred Stock may initially convert into Common Stock at $6.10 per share and pays cumulative dividends at 10% per annum until September 13, 2027, increasing to 12% per annum thereafter.¶3
The Company agreed to register the resale of shares issuable upon conversion or warrant exercise, seek shareholder approval for issuance exceeding 19.99% of outstanding Common Stock, and filed the Certificate of Designation creating the Series M preferred stock rights.¶4¶5¶6¶7
On September 3, 2026, Hubilu Venture Corporation, through Elata Investments, LLC, entered an agreement with Finance of America Reverse LLC to acquire 5717 4th Ave in Los Angeles, and the acquisition closed on September 11, 2026.¶1
The filing also states that the property was vacant at purchase and that the acquisition closed on August 10, 2026, subject to a $550,000 first position note bearing 9.990% annual interest.¶2
